BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Unlike chronic myeloid leukemia (CML), where single treatment with BCR-ABL inhibitors has been proven very successful, the use of single kinase inhibitors in AML has not dramatically altered outcomes as in CML [12–14].